Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IL12-MSLN CAR NK cells
- Development stage
- Preclinical
- Lead developer
- Allife Medical Science and Technology
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, CAR-Macrophages → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
IL12-MSLN CAR NK cells are genetically engineered natural killer (NK) cells designed for cancer immunotherapy. These cells are modified to express a chimeric antigen receptor (CAR) targeting mesothelin (MSLN), a membrane glycoprotein overexpressed on various solid tumors, notably in ovarian, pancreatic, and certain hematologic cancers. In addition, they are engineered to secrete interleukin-12 (IL-12), a cytokine known to enhance anti-tumor immune responses. The combination improves the NK cells' activation, metabolic fitness, cytotoxicity, and cytokine production. IL12-MSLN CAR NK cells have demonstrated increased killing of MSLN-positive cancer cells, higher IFN-γ production, and greater induction of MHC I/II on target tumor cells compared to MSLN CAR NK cells lacking IL-12. Preclinical studies in acute myeloid leukemia (AML) and solid tumors have shown promising efficacy, supporting their further evaluation in relapsed/refractory MSLN-positive malignancies[1][2][3].
- Other names
- IL-12–engineered mesothelin CAR NK cellsIL12-MSLN CAR CIML NK cellsIL-12-MSLN CAR CIML NK cellsIL 12-MSLN CAR CIML NK cells
02
Targets
IL-12R (Interleukin-12 receptor)Mesothelin
Beyond the preview
Go deeper on IL12-MSLN CAR NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IL12-MSLN CAR NK cells.